A microRNA‐clinical prognosis model to predict the overall survival for kidney renal clear cell carcinoma

Zhan, Yating; Zhang, Rongrong; Li, Chunxue; Xu, Xuantong; Zhu, Kai; Yang, Zhan; Zheng, Jianjian; Guo, Yong

doi:10.1002/cam4.4148

Cited by 7 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[36] revealed that miR-3613-5p was prognostic for renal clear cell carcinoma, which was also observed in the study by Zhan Y et al [37] Ma J et al…”

Section: Discussionsupporting

confidence: 65%

An immune-related microRNA signature prognostic model for pancreatic carcinoma and association with immune microenvironment

Shen

Pan

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective To establish a prognostic model based on immune-related microRNA (miRNA) for pancreatic carcinoma. Methods Weighted correlation network analysis (WGCNA) was performed using the "WGCNA" package to find the key module genes involved in pancreatic carcinoma. Spearman correlation analysis was conducted to screen immune-related miRNAs. Uni- and multi-variate COX regression analyses were carried out to identify miRNAs prognostic for overall survival (OS) of pancreatic carcinoma, which were then combined to generate a prognostic model. Kaplan-Meier survival analysis, receiver operating characteristic (ROC) analysis, distribution plot of survival status in patients and regression analysis were collectively performed to study the accuracy of the model in prognosis. Target genes of the miRNAs in the model were intersected with the key module genes, and a miRNA-mRNA network was generated and visualized by Cytoscape3.8.0. TIMER analysis was conducted to study the abundance of immune infiltrates in tumor microenvironment of pancreatic carcinoma. Expression levels of immune checkpoint genes in subgroups stratified by the model were compared by Wilcoxon test. Gene Set Enrichment Analysis (GSEA) was performed to analyze the enriched signaling pathways between subgroups. Results Differential analysis revealed 1,826 genes differentially up-regulated in pancreatic carcinoma and 1,276 genes differentially down-regulated. A total of 700 immune-related miRNAs were obtained, of which 7 miRNAs were significantly associated with OS of patients and used to establish a prognostic model with accurate predictive performance. There were 99 mRNAs overlapped from the 318 target genes of the 7 miRNAs and the key modules genes analyzed by WGCNA. Patient samples were categorized as high or low risk according to the prognostic model, which were significantly associated with dendritic cell infiltration and expression of immune checkpoint genes (TNFSF9, TNFRSF9, KIR3DL1, HAVCR2, CD276 and CD80). GSEA showed remarkably enriched signaling pathways in the two subgroups. Conclusion This study identified an immune-related 7-miRNA based prognostic model for pancreatic carcinoma, which could be used as a reliable tool for prognosis.

show abstract

“…[36] revealed that miR-3613-5p was prognostic for renal clear cell carcinoma, which was also observed in the study by Zhan Y et al [37] Ma J et al…”

Section: Discussionsupporting

confidence: 65%

An immune-related microRNA signature prognostic model for pancreatic carcinoma and association with immune microenvironment

Shen

Pan

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…miR-1269a is highly expressed in 9 cancers, including hepatocellular carcinoma (Wojcicka et al, 2014;Yang et al, 2014;Gan et al, 2015;Elemeery et al, 2017;Wang et al, 2019;Cho et al, 2020), lung cancer (Bao et al, 2018;Jin et al, 2018;Guo et al, 2020;Wang et al, 2020;Du et al, 2021;Le and Le, 2021), gastric cancer (Liu et al, 2019;Zhang K. et al, 2020), colon cancer (Bu et al, 2015;Xiong et al, 2021), esophageal cancer (Bai et al, 2021;Yu and Ren, 2021;Zhao et al, 2021), clear cell renal cell carcinoma (Qin et al, 2019;Zhan et al, 2021), head and neck squamous cell carcinoma (Nunez Lopez et al, 2018), glioma , and acute myeloid leukemia (Li and Ge, 2021). Highly expressed miR-1269a can promote cancer cell proliferation, migration, invasion, epithelial-mesenchymal transition, and inhibit cancer cell apoptosis (Table 1).…”

Section: Oncological Role Of Mir-1269a and Mir-1269b In Cancermentioning

confidence: 99%

“…The expression levels of miR-1269a and miR-1269b are significantly related to the prognosis of cancer patients (Table 2). The high expression of miR-1269a is significantly associated with the lower overall survival (OS) of 6 kinds of cancer patients, including hepatocellular carcinoma (Cho et al, 2020), esophageal squamous cell carcinoma (Jang et al, 2017;Bai et al, 2021;Yu and Ren, 2021), lung cancer (Guo et al, 2020), clear cell renal cell carcinoma (Qin et al, 2019;Zhan et al, 2021), glioma and acute myeloid leukemia (Li and Ge, 2021). In hepatocellular carcinoma, high expression of miR-1269a is significantly associated with shorter disease-free survival (DFS) in patients with hepatocellular carcinoma (Cho et al, 2020) and lower cancer-specific survival (CSS) in patients with esophageal squamous cell carcinoma (Yu and Ren, 2021).…”

Section: The Diagnostic and Prognostic Value Of Mir-1269mentioning

confidence: 99%

miR-1269a and miR-1269b: Emerging Carcinogenic Genes of the miR-1269 Family

Xie

Zhong

Duan

2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

miRNAs play an important role in the occurrence and development of human cancer. Among them, hsa-mir-1269a and hsa-mir-1269b are located on human chromosomes 4 and 17, respectively, and their mature miRNAs (miR-1269a and miR-1269b) have the same sequence. miR-1269a is overexpressed in 9 cancers. The high expression of miR-1269a not only has diagnostic significance in hepatocellular carcinoma and non-small cell lung cancer but also is related to the poor prognosis of cancer patients such as esophageal cancer, hepatocellular carcinoma, and glioma. miR-1269a can target 8 downstream genes (CXCL9, SOX6, FOXO1, ATRX, RASSF9, SMAD7, HOXD10, and VASH1). The expression of miR-1269a is regulated by three non-coding RNAs (RP11-1094M14.8, LINC00261, and circASS1). miR-1269a participates in the regulation of the TGF-β signaling pathway, PI3K/AKT signaling pathway, p53 signaling pathway, and caspase-9-mediated apoptotic pathway, thereby affecting the occurrence and development of cancer. There are fewer studies on miR-1269b compared to miR-1269a. miR-1269b is highly expressed in hepatocellular carcinoma, non-small cell lung cancer, oral squamous cell carcinoma, and pharyngeal squamous cell carcinoma, but miR-1269b is low expressed in gastric cancer. miR-1269b can target downstream genes (METTL3, CDC40, SVEP1, and PTEN) and regulate the PI3K/AKT signaling pathway. In addition, sequence mutations on miR-1269a and miR-1269b can affect their regulation of cancer. The current studies have shown that miR-1269a and miR-1269b have the potential to be diagnostic and prognostic markers for cancer. Future research on miR-1269a and miR-1269b can focus on elucidating more of their upstream and downstream genes and exploring the clinical application value of miR-1269a and miR-1269b.At present, there is no systematic summary of the research on miR-1269a and miR-1269b. This paper aims to comprehensively analyze the abnormal expression, diagnostic and prognostic value, and molecular regulatory pathways of miR-1269a and miR-1269b in multiple cancers. The overview in our work can provide useful clues and directions for future related research.

show abstract